Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aripiprazole as Adjunctive Therapy in Major Depressive Disorder
NCT00095823Phase 3Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Jun 2004
- Primary completion
- Aug 2006
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of aripiprazole in major depressive disorder (MDD) (3 arms), sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoint: Change in a depression rating scale at 14 weeks. Started Jun 2004; status: completed.
02
Drugs
aripiprazole
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00095823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00095823.